Addressing the Unique Challenges of Data Management in ADC Development White Paper Authors: Dr. Eliot Randle, Ph.D., Independent Consultant in the Biopharmaceutical Industry Joe DiMartino, Luminata Solution Manager, ACD/LabsIntroduction Antibody Drug Conjugates (ADCs), or immunoconjugates, are an increasingly important sub-class of antibody-related therapeutics. ADCs leverage the specificity of monoclonal antibodies (mAbs) to enable targeted drug delivery to tumor cells while minimizing or eliminating damage to healthy tissue, thus reducing the disruptive side effects associated with traditional chemotherapy drugs. In addition to their ability to directly target tumor cells with a cytotoxic drug, ADCs are also showing promise for their ability to indirectly treat tumors by deliverin

Join for free to read